Overview

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer
Phase:
Phase 2
Details
Lead Sponsor:
Hao Long
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Pemetrexed